Matter of life and death: The pharmacological approaches targeting apoptosis in brain diseases

Current Pharmaceutical Design

Volumn 17, Issue 3, 2011, Pages 215-229

  Cavallucci, Virve ^a   D'Amelio, Marcello ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anti apoptotic therapies; Cell death; Mitochondria; Neurodegenerative diseases; Oxidative stress

Indexed keywords

4 GUANIDINO N BUTYL SYRINGATE; ANTIPARKINSON AGENT; ASTAXANTHIN; CARBOLITHIUM; CASPASE INHIBITOR; CATECHOL METHYLTRANSFERASE INHIBITOR; DILTIAZEM; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IDEBENONE; LEVODOPA; LITHIUM; LITHIUM CARBONATE; MALONIC ACID; MECLOZINE; MELATONIN; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; MORIN; OSTHOLE; RAPAMYCIN; RECOMBINANT GIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RILUZOLE; SCM 198; TAT BCL XL FUSION PROTEIN; TETANUS TOXOID; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; Z VAK FMK;

ADD ON THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BIPOLAR DISORDER; BRAIN DAMAGE; BRAIN INJURY; BRAIN MITOCHONDRION; DEGENERATIVE DISEASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; ENZYME ACTIVATION; GENE MUTATION; HEALTH CARE COST; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; NAUSEA AND VOMITING; NEUROPATHOLOGY; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TARGET CELL; VERTIGO; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; APOPTOSIS; BRAIN DISEASES; BRAIN INJURIES; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; RATS;

EID: 79955978036     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795049705     Document Type: Review

References (202)

1. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1990; 68: 251-306.
2. Rich T, Watson CJ, Wyllie AH. Apoptosis: the germs of death. Nat Cell Biol 1999; 1: E69-71.
3. Fuentes-Prior P, Salvesen G. The protein structures that shape caspase-activity, specificity, activation and inhibition. Biochem J 2004; 384: 201-32.
4. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME.Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439-59.
5. Green DR and Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-629.
6. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-19.
7. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
8. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115: 565-71.
9. Er E, Oliver L, Cartron PF, Juin P, Manon S, Vallette M. Mitochondria as the target of pro-apoptotic protein Bax. Biochim BiophysActa 2006; 1757: 1301-11.
10. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
11. Acehan D, Jiang X, Morgan DG, Heuser JE, Wang X, Akey CW. Three-dimensional structure of the apoptosome. Implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002; 9: 423-32.
12. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
13. Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAPinteraction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-6.
14. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10.
15. Yang X, Chang HY, Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell 1998; 1: 319-25.
16. Peter EM, Krammer PH. The CD95 (Apo-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
17. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-87.
18. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-700.
19. Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385-90.
20. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
21. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-5.
22. Rabizadeh S, Gralla EB, Borchelt DR, et al. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci USA 1995; 92: 3024-28.
23. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci. 1997; 17: 8756-66.
24. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58: 459-71.
25. Vukosavic S, Dubois-Dauphin M, Romero N, Przedborski S. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999; 73: 2460-8.
26. Vukosavic S, Stefanis L, Jackson-Lewis V, et al. Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000; 20: 9119-25.
27. Pasinelli, P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and caspase-3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 13901-6.
28. Guégan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001; 21: 7569-76.
29. Li M, Ona VO, Guégan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-9.
30. Kostic V, Jackson-Lewis V, Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: Prolonged life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-62.
31. Friedlander RM, Brown RH Jr, Gagliardini V, Wang J, Yuan J. Inhibition of ICE slows ALS in mice. Nature 1997; 388: 31.
32. Inoue H, Tsukita K, Iwasato T, et al. The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model.EMBO J 2003; 22: 6665-74.
33. Kieran D, Woods I, Villunger A, Strasser A, Prehn JHM. Deletion of the BH3-only protein puma protects motoneurons from ER stress-induced apoptosis and delays motoneuron loss in ALS mice. Proc Natl Acad Sci USA 2007; 104: 20606-11.
34. Reyes NA, Fisher JK, Austgen K, VandenBerg S, Huang EJ, Oakes SA. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest 2010; 120: 3673-9.
35. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-8.
36. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron1995; 14: 1105-16.
37. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995; 676: 25-40.
38. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18: 3241-50.
39. Sotelo-Silveira JR, Lepanto P, Elizondo V, et al. Axonal mitochondrial clusters containing mutant SOD1 in transgenic models of ALS. Antioxid Redox Signal 2009; 11: 1535-45.
40. Menzies FM, Cookson MR, Taylor RW, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002; 125: 1522-33.
41. Raimondi A, Mangolini A, Rizzardini M, et al. Cell culture models to investigate the selective vulnerability of motoneuronal mitochondria to familial ALS-linked G93ASOD1. Eur J Neurosci 2006; 24: 387-99.
42. Carri MT, Ferri A, Battistoni A, et al. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett 1997; 414: 365-8.
43. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998; 153: 135-42.
44. Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 2002; 83: 535-45.
45. Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007; 500: 20-46.
46. Fukada K, Zhang F, Vien A, Cashman NR, Zhu H. Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics 2004; 3: 1211-23.
47. Wood-Allum CA, Barber SC, Kirby J, et al. Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain 2006; 129:1693-709.
48. Sasaki S, Iwata M. Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. Neurosci Lett 1996; 204: 53-6.
49. Siklos L, Engelhardt J, Harati Y, Smith RG, Joo F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol 1996; 39: 203-16.
50. Falcon J. Cellular circadian clocks in the pineal. Prog Neurobiol 1999; 58: 121-62.
51. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-97.
52. Wang X. The anti-apoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009; 15: 345-57.
53. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006; 41: 313-23.
54. Henderson CE, Phillips HS, Pollock RA, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062-4.
55. Oppenheim RW, Houenou LJ, Johnson JE, et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995; 373: 344-6.
56. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995; 373: 341-4.
57. Sagot Y, Tan SA, Hammang JP, Aebischer P, Kato AC. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. J Neurosci 1996; 16: 2335-41.
58. Haase G, Kennel P, Pettmann B, et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997; 3: 429-36.
59. Alisky JM, Davidson BL. Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum Gene Ther 2000; 11: 2315-29.
60. Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adenoassociated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-8.
61. Li W, Brakefield D, Pan Y, Hunter D, Myckatyn TM, Parsadanian A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol 2007; 203: 457-71.
62. Coen L, Osta R, Maury M, Brulet P. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system. Proc Natl Acad Sci USA 1997; 94: 9400-5.
63. Herreros J, Lalli G, Schiavo G. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem J 2000; 347: 199-204.
64. Ciriza J, Moreno-Igoa M, Calvo AC, et al. A genetic fusion GDNF-C fragment of tetanus toxin prolongs survival in symptomatic mouse ALS model. Restor Neurol Neurosci 2008; 26: 459-65.
65. Chuang DM, Chen RW, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002; 4: 129-36.
66. Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat Neuneurodegenerative diseases? Crit Rev Neurobiol 2004; 16: 83-90.
67. Young W. Review of lithium effects on brain and blood. Cell Transplant 2009;18: 951-75.
68. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105: 2052-7.
69. Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083-98.
70. Pitzer C, Krüger C, Plaas C, et al. Granulocytecolony stimulating factor improves outcome in a mouse model of amyotrophic lateralsclerosis. Brain 2008; 131: 3335-47.
71. Henriques A, Pitzer C, Dupuis L, Schneider A. G-CSF protects motoneurons against axotomy-induced apoptotic death in neonatal mice. BMC Neurosci 2010; 11: 25.
72. Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A. CNS-targeted viral delivery of G-CSF in an animal model for ALS: Improved efficacy and preservation of the neuromuscular unit. Mol Ther 2010 Dec 7 [Epub ahead of print].
73. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-96.
74. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 36: 2112-7.
75. Price BH, Gurvit H, Weintraub S, Geula C, Leimkuhler E, Mesulam M. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch Neurol 1993; 50: 931-7.
76. Greene JD, Baddeley AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia 1996; 34: 537-51.
77. Esteban-Santillan C, Praditsuwan R, Ueda H, Geldmacher DS. Clock drawing test in very mild Alzheimer's disease J Am Geriatr Soc 1998; 46: 1266-9.
78. Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003; 74:1206-9.
79. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
80. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
81. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
82. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-56.
83. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004; 25: 641-50.
84. Behl C. Apoptosis and Alzheimer's disease. J Neural Transm 2000; 107: 1325-44.
85. Colurso GJ, Nilson JE, Vervoort LG. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Sci 2003; 73: 1795-803.
86. Selznick LA, Holtzman DM, Han BH, et al. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol 1999; 58: 1020-6.
87. Estus S, Zaks WJ, Freeman RS, Gruda M, Bravo R, Johnson, EM Jr. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 1994; 127: 1717-27.
88. Su JH, Den, G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 1997; 56: 86-93.
89. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer's disease and mild cognitive impairment. Neurology 2007; 68: 1501-8.
90. Chagnon P, Betard C, Robitaille Y, Cholette A, Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport 1995; 6: 711-5.
91. Stadelmann C, Deckwerth TL, Srinivasan A, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 1999; 155: 1459-66.
92. Lu DC, Rabizadeh S, Chandra S, et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 2000; 6: 397-404.
93. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000; 924: 17-25.
94. Puttfarcken PS, Manelli AM, Neilly J, Frail DE. Inhibition of ageinduced β-amyloid neurotoxicity in rat hippocampal cells. Exp Neurol 1996; 138: 73-81.
95. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90: 7951-5.
96. Ivins KJ, Bui ET, Cotman CW. Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis 1998; 5: 365-78.
97. Ivins KJ, Thornton PL, Rohn TT, Cotman CW. Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol Dis 1999; 6: 440-9.
98. Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K. Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 1992; 267; 18210-7.
99. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004; 24: 565-75.
100. Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 2001; 281: 468-74.
101. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-89.
102. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
103. Parks JK, Smith TS, Trimmer PA, Bennett JP Jr, Parker WD Jr. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 2001; 76: 1050-6.
104. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006; 15: 1437-49.
105. Hansson CA, Frykman S, Farmery MR, et al. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 2004; 279: 51654-60.
106. Moreira PI, Santos MS, Moreno A, Rego AC, Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 2002; 69: 257-67.
107. Saraiva LM, Seixas da Silva GS, Galina A, et al. Amyloid-[1] triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One 2010; 5: e15230.
108. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62: 649-71.
109. Wang Z, Gardiner NJ, Fernyhough P. Blockade of hexokinase activity and binding to mitochondria inhibits neurite outgrowth in cultured adult rat sensory neurons. Neurosci Lett. 2008; 434: 6-11.
110. da-Silva WS, Gomez-Puyou A, De Gomez-Puyou MT, et al. Mitochondrial Bound Hexokinase Activity as a Preventive Antioxidant Defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive species generation in mitochondria. J Biol Chem 2004; 279: 39846-55.
111. D'Amelio M, Cavallucci V, Middei S, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011; 14: 69-76.
112. Hyman BT. Caspase activation without apoptosis: insight into A[1] initiation of neurodegeneration. Nat Neurosci 2011; 14: 5-6.
113. Kent A: Huntington's disease. Nurs Stand, 2004; 21: 45-51.
114. Ropper AH, Brown RH. Principles of Neurology. 8th ed. McGraw-Hill 2005.
115. MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
116. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994; 330: 1401-6.
117. Rubinsztein DC, Leggo J, Coles R, et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 1996; 59: 16-22.
118. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
119. Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537-48.
120. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-3.
121. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA 1998; 95: 6480-5.
122. Dragunow M, Faull RL, Lawlor P, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995; 6: 1053-7.
123. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995;15: 3775-87.
124. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 1995;133: 265-72.
125. Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998; 87: 49-53.
126. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999; 22: 623-33.
127. Graham RK, Deng Y, Carroll J, et al. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci 2010; 30: 15019-29.
128. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Hntington's disease. Nature 1999; 399: 263-7.
129. Li SH, Lam S, Cheng AL, Li XJ. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum Mol Genet 2000; 9: 2859-67.
130. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
131. Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 1996; 13: 442-9.
132. Wellington CL, Ellerby LM, Hackam AS, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998; 273: 9158-67.
133. Kiechle T, Dedeoglu A, Kubilus J, et al. Cytochrome c and caspase-9 expression in Huntington's disease. Neuromolecular Med 2002; 1: 183-95.
134. Zhang Y, Ona VO, Li M. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem 2003; 87: 1184-92.
135. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23: 298-304.
136. Joza N, Kroemer G, Penninger JM. Genetic analysis of the mammalian machinery. Trends Genet 2002; 18: 142-9.
137. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983; 5. 605-9.
138. Ayala A, Venero JL, Cano J, Machado A. Mitochondrial toxins and neurodegenerative diseases. Front Biosci 2007; 12: 986-1007.
139. Andreassen OA, Ferrante RJ, Hughes DB, et al. Malonate and 3- nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. J Neurochem 2000; 75: 847-52.
140. Toulmond S, Tang K, Bureau Y, et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol 2004; 141: 689-97.
141. Gohil VM, Sheth SA, Nilsson R, et al. Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat Biotechnol 2010; 28: 249-55.
142. Gohil VM, Offner N, Walker JA, et al. Meclizine is neuroprotective in models of Huntington's disease. Hum Mol Genet 2011;20: 294-300.
143. Tunez I, Montilla P, Del Carmen Munoz M, Feijoo M, Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 2004; 37: 252-6.
144. Southgate G, Daya S. Melatonin reduces quinolinic acid-induced lipid peroxidation in rat brain homogenate. Metab Brain Dis 1999; 14: 165-71.
145. Wang X, Zhu S, Pei Z, et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 2008; 28: 9473-85.
146. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004; 5: 373-84.
147. Santamaría A, Ríos C. MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci Lett 1993; 159: 51-4.
148. Araujo DM, Cherry SR, Tatsukawa KJ, Toyokuni T, Kornblum HI. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Exp Neurol 2000; 166: 287-97.
149. Kalonia H, Kumar P, Kumar A. Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. Brain Res 2010 Nov 26 [Epub ahead of print].
150. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular Pathophysiologyof Parkinson's Disease. Annu Rev Neurosci 2005; 28: 57-87.
151. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259-72.
152. Schulz JB. Update on the pathogenesis of Parkinson's disease J Neurol 2008; 255 (Suppl 5): 3-7.
153. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137: 120-3.
154. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000; 97: 2875-80.
155. Bloem BR, Irwin I, Buruma OJS, et al. The MPTP model: versatile contributions to the treatment. J Neurol Sci 1990; 97: 273-93.
156. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993; 61: 1191-206.
157. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 2000; 283: 193-6.
158. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridinetreated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997; 77: 1037-48.
159. Eberhardt O, Coelln RV, Kugler S, et al. Protection by synergistic effects of adenovirus-mediated X chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2000; 20: 9126-34.
160. Crocker SJ, Liston P, Anisman H, et al. Attenuation of MPTPinduced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice. Neurobiol Dis 2003; 12: 150-61.
161. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004; 304:1328-31.
162. Tsang AH, Lee YI, Ko HS, et al. S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci USA 2009; 106: 4900-5.
163. Vila M, Jackson-Lewis V, Vukosavic S, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 2837-42.
164. Dietz GPH, Stockhausen KV, Dietz B, et al. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J Neurochem 2008; 104: 757-65.
165. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors andParkinson's disease: a case-control study in Taiwan. Neurology 1997; 48: 1583-8.
166. McCormack AL, Thiruchelvam M, Manning-Bog AB, et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002; 10: 119-27.
167. Fei Q, McCormack AL, Di Monte DA, Ethell DW. Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem 2008; 283: 3357-64.
168. Yamada M, Kida K, Amutuhaire W, Ichinose F, Kaneki M. Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 2010; 402: 312-8.
169. Yacoubian TA, Slone SR, Harrington AJ, et al. Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death Dis 2010; 1.
170. Lee DH, Kim CS, Lee YJ. Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol 2011; 49:271-80.
171. Zhang ZT, Cao XB, Xiong N, et al. Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. Acta Pharmacol Sin 2010; 31: 900-6.
172. Liu WB, Zhou J, Qu Y, et al. Neuroprotective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. Neurochem Int 2010; 57: 206-15.
173. Shi XR, Hong ZY, Liu HR, Zhang YC, Zhu YZ. Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioural deficit in rats and cytotoxicity in neuronal SH-SY5Y cells. Neurochem Int.
174. Choi DW. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci 1994; 747: 162-71.
175. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982; 11: 491-8.
176. Benchoua A, Guegan C, Couriaud C, et al. Specific caspase pathways are activated in the two stages of cerebral infarction. Neurosci 2001; 21: 7127-34.
177. Friedlander RM, Gagliardini V, Hara H, et al. Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med 1997; 185: 933-40.
178. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M. Inhibition of caspase-1-like activity by Ac-Tyr-Val- Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci 2000; 20: 4398-404.
179. Kang SJ, Wang S, Hara H, et al. Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol 2000; 149: 613-22.
180. Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994; 13: 1017-30.
181. Plesnila N, Zinkel S, Le DA, et al. BID mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. Proc Natl Acad Sci USA 2001; 98: 15318-23.
182. Fink K, Zhu J, Namura S, et al. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab 1998; 18: 1071-6.
183. Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1 beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94: 2007-12.
184. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci 2010; 13: 805-11.
185. Rubinsztein DC, Nixon RA. Rapamycin induces autophagic flux in neurons. Proc Natl Acad Sci USA 2010; 107: E181.
186. Carloni S, Buonocore G, Balduini W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol Dis 2008; 32: 329-39.
187. Tolkovsky AM, Xue L, Fletcher GC, Borutaite V. Mitochondrial disappearance from cells: a clue to the role of autophagy in programmed cell death and disease? Biochimie 2002; 84: 233-40.
188. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res 2005; 8: 3-5.
189. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004; 73: 87-106.
190. Victor VM, Rocha M. Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des 2007; 13: 845-63.
191. Norenberg MD, Rao KV. The mitochondrial permeability transition in neurologic disease. Neurochem Int 2007; 50: 983-97.
192. Genova ML, Pich MM, Biondi A, et al. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp Biol Med (Maywood) 2003; 228: 506-13.
193. Lu C, Zhang D, Whiteman M, Armstrong JS. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid Redox Signal 2008; 10: 651-60.
194. Suno M, Nagaoka A. Inhibition of lipid peroxidation by idebenone in brain mitochondria in the presence of succinate. Arch GerontolGeriatr 1989; 8: 291-7.
195. Zhu YG, Chen XC, Chen ZZ, Zeng YQ, Shi GB, Su YH, Peng X. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin 2004; 25: 1606-12.
196. Su B, Wang X, Nunomura A, et al. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 525-32.
197. Truelsen T, Thudium D, Grønbaek M. Copenhagen City Heart Study. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 2002; 59: 1313-9.
198. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004; 3: 579-87.
199. Miller NJ, Rice-Evans CA. Antioxidant activity of resveratrol in red wine. Clin Chem 1995; 41: 1789.
200. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's Disease. Mol Neurodegener 2008; 21: 3-15.
201. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993: 334-44.
202. Klivenyi P, Ferrante RJ, Matthews RT. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-50.